Payment overview · 2025
General Payments
$618.28
30 reported records · 15 companies
Healthcare provider profile · identity verified
Leanne Knowles, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · VALLEY, AL · NPI 1447635305
Verified facts
What the public records show
CMS Open Payments records show Leanne Knowles, CRNP received $618.28 in general payments during 2025 across 30 reported records.
Novartis Pharmaceuticals Corporation accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Creon by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $122.28 | 19.8% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $82.06 | 13.3% | 3 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $59.49 | 9.6% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $44.50 | 7.2% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $43.79 | 7.1% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $39.83 | 6.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $38.77 | 6.3% | 2 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $36.92 | 6.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.71 | 5.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.18 | 4.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $19.74 | 3.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.27 | 3.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.22 | 2.8% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.79 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.73 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.28 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $82.79 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $82.06 | 3 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $59.49 | 3 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $44.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 416 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 301 | 113 |
| Famotidine | Famotidine | 279 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 66 |
| Omeprazole | Omeprazole | 260 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 80 |
| Trazodone Hcl | Trazodone Hcl | 251 | 53 |
| Losartan Potassium | Losartan Potassium | 236 | 75 |
| Alprazolam | Alprazolam | 209 | 45 |
| Potassium Chloride | Potassium Chloride | 199 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 59 |
| Simvastatin | Simvastatin | 179 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 50 |
| Lisinopril | Lisinopril | 172 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 63 |
| Carvedilol | Carvedilol | 158 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 45 |
| Prednisone | Prednisone | 134 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 58 |
| Metformin Hcl | Metformin Hcl | 130 | 40 |
| Furosemide | Furosemide | 126 | 33 |
| Montelukast Sodium | Montelukast Sodium | 122 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 29 |
| Fluconazole | Fluconazole | 119 | 73 |
| Clonidine Hcl | Clonidine Hcl | 114 | 27 |
| Meloxicam | Meloxicam | 113 | 32 |
| Celecoxib | Celecoxib | 112 | 30 |
| Ozempic | Semaglutide | 107 | 20 |
| Methylprednisolone | Methylprednisolone | 103 | 81 |
| Tramadol Hcl | Tramadol Hcl | 101 | 29 |
| Sucralfate | Sucralfate | 99 | 55 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 38 |
| Ibuprofen | Ibuprofen | 97 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 78 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 34 |
| Mirtazapine | Mirtazapine | 89 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 21 |
| Methocarbamol | Methocarbamol | 87 | 23 |
| Clonazepam | Clonazepam | 85 | 18 |
| Sertraline Hcl | Sertraline Hcl | 83 | 19 |
| Farxiga | Dapagliflozin Propanediol | 78 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 20 |
| Pregabalin | Pregabalin | 76 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 17 |
| Alendronate Sodium | Alendronate Sodium | 70 | 24 |
| Amoxicillin | Amoxicillin | 70 | 49 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 67 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 15 |
| Buspirone Hcl | Buspirone Hcl | 62 | 13 |
| Azithromycin | Azithromycin | 61 | 56 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Allopurinol | Allopurinol | 52 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 16 |
| Nystatin | Nystatin | 51 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Jardiance | Empagliflozin | 49 | 11 |
| Mounjaro | Tirzepatide | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 11 |
| Baclofen | Baclofen | 44 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Creon | Lipase/Protease/Amylase | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 11 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Topiramate | Topiramate | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 24 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 28 |
| Glimepiride | Glimepiride | 31 | 12 |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Mupirocin | Mupirocin | 23 | 12 |
| Ofloxacin | Ofloxacin | 23 | 13 |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Armodafinil | Armodafinil | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.28 · 30 records | Novartis Pharmaceuticals Corporation | ELIGARD, EPKINLY, Enhertu, Hizentra, IMBRUVICA, JAKAFI, KEYTRUDA, KISQALI, LIBTAYO, LYNPARZA, Lenvima, MONJUVI, ORGOVYX, PLUVICTO, QINLOCK, ROMVIMZA, Vonjo, ZEPZELCA, ZYNYZ, Zoladex, clonoSEQ | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error